These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 35764491)

  • 61. Real-World Evidence of the Clinical and Economic Impact of Long-Acting Injectable Versus Oral Antipsychotics Among Patients with Schizophrenia in the United States: A Systematic Review and Meta-Analysis.
    Lin D; Thompson-Leduc P; Ghelerter I; Nguyen H; Lafeuille MH; Benson C; Mavros P; Lefebvre P
    CNS Drugs; 2021 May; 35(5):469-481. PubMed ID: 33909272
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Real-World Adherence and Persistence to Oral Disease-Modifying Therapies in Multiple Sclerosis Patients Over 1 Year.
    Johnson KM; Zhou H; Lin F; Ko JJ; Herrera V
    J Manag Care Spec Pharm; 2017 Aug; 23(8):844-852. PubMed ID: 28737986
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Development of a standardized guide for optimizing drug adherence information to be dispensed during a pharmaceutical counseling with a multiple myeloma patient: Initial validation].
    Favier-Archinard C; Leguelinel-Blache G; Dubois F; Le Gall T; Bourquard P; Passemard N; Tora S; Rey A; Rossi M; Chevallier T; Cousin C; Favier M
    Bull Cancer; 2018 May; 105(5):475-485. PubMed ID: 29573809
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Healthcare resource utilization among patients with relapsed multiple myeloma in the UK, France, and Italy.
    Gonzalez-McQuire S; Yong K; Leleu H; Mennini FS; Flinois A; Gazzola C; Schoen P; Campioni M; DeCosta L; Fink L
    J Med Econ; 2018 May; 21(5):450-467. PubMed ID: 29278014
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Treatment of multiple myeloma in the targeted therapy era.
    Saad AA; Sharma M; Higa GM
    Ann Pharmacother; 2009 Feb; 43(2):329-38. PubMed ID: 19193585
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Risk of rash associated with lenalidomide in cancer patients: a systematic review of the literature and meta-analysis.
    Nardone B; Wu S; Garden BC; West DP; Reich LM; Lacouture ME
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):424-9. PubMed ID: 23769670
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy of maintenance treatment in patients with multiple myeloma: a systematic review and network meta-analysis.
    Zhi Y; Bao S; Mao J; Chai G; Zhu J; Liu C; Chen X
    Hematology; 2022 Dec; 27(1):1069-1088. PubMed ID: 36125238
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
    Delforge M; Minuk L; Eisenmann JC; Arnulf B; Canepa L; Fragasso A; Leyvraz S; Langer C; Ezaydi Y; Vogl DT; Giraldo-Castellano P; Yoon SS; Zarnitsky C; Escoffre-Barbe M; Lemieux B; Song K; Bahlis NJ; Guo S; Monzini MS; Ervin-Haynes A; Houck V; Facon T
    Haematologica; 2015 Jun; 100(6):826-33. PubMed ID: 25769541
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review.
    Wang Y; Yang F; Shen Y; Zhang W; Wang J; Chang VT; Andersson BS; Qazilbash MH; Champlin RE; Berenson JR; Guan X; Wang ML
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582244
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
    Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
    Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Comprehensive Review of Methods to Measure Oral Oncolytic Dose Intensity Using Retrospective Data.
    Slejko JF; Rueda JD; Trovato JA; Gorman EF; Betz G; Arcona S; Zacker C; Stuart B
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1125-1132. PubMed ID: 31556821
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Advances in maintenance strategy in newly diagnosed multiple myeloma patients eligible for autologous transplantation.
    Wahab A; Rafae A; Faisal MS; Mushtaq K; Ehsan H; Khakwani M; Ashraf A; Rehan T; Ahmed Z; Shah Z; Khan A; Anwer F
    Expert Rev Hematol; 2020 Dec; 13(12):1333-1347. PubMed ID: 33078986
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Primary Nonadherence to Oral Anticoagulants in Patients with Atrial Fibrillation: Real-World Data from a Population-Based Cohort.
    Rodriguez-Bernal CL; Peiró S; Hurtado I; García-Sempere A; Sanfélix-Gimeno G
    J Manag Care Spec Pharm; 2018 May; 24(5):440-448. PubMed ID: 29694286
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.
    Palmer MJ; Machiyama K; Woodd S; Gubijev A; Barnard S; Russell S; Perel P; Free C
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD012675. PubMed ID: 33769555
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Novel therapies in multiple myeloma for newly diagnosed nontransplant candidates.
    Kristinsson SY; Landgren O; Rajkumar VS
    Cancer J; 2009; 15(6):473-8. PubMed ID: 20010166
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Reminder packaging for improving adherence to self-administered long-term medications.
    Mahtani KR; Heneghan CJ; Glasziou PP; Perera R
    Cochrane Database Syst Rev; 2011 Sep; (9):CD005025. PubMed ID: 21901694
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial.
    Gay F; Musto P; Rota-Scalabrini D; Bertamini L; Belotti A; Galli M; Offidani M; Zamagni E; Ledda A; Grasso M; Ballanti S; Spadano A; Cea M; Patriarca F; D'Agostino M; Capra A; Giuliani N; de Fabritiis P; Aquino S; Palmas A; Gamberi B; Zambello R; Petrucci MT; Corradini P; Cavo M; Boccadoro M
    Lancet Oncol; 2021 Dec; 22(12):1705-1720. PubMed ID: 34774221
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Lenalidomide: a review of its continuous use in patients with newly diagnosed multiple myeloma not eligible for stem-cell transplantation.
    McCormack PL
    Drugs Aging; 2015 May; 32(5):409-18. PubMed ID: 25925941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.